CSL Vifor

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals

Other Names/Subsidiaries

  • Vifor Pharma Group, Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
  • Galenica Group
  • Relypsa, Inc.
  • Vifor Pharma
  • Vifor-Fresenius Medical Care Renal Pharma Ltd.
  • OM Pharma
  • Sanifit Therapeutics S.A.
See more in Biomedtracker

Latest on CSL Vifor

Scrip

Stock Watch: Hesitant Vaccine Sales For CSL Reflect Wider Issues

 
• By Andy Smith

CSL’s Opening And Closing Doors Near the end of fourth-quarter 2024 earnings season for life science companies, Australia’s CSL reported its half-year results. Its stock price initially increased by a

Scrip

Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Scrip

UK Urged To Protect R&D Tax Credits, The Lifeblood Of Biotechs

 
• By Kevin Grogan

R&D tax credits have played a vital role in advancing UK life science, mitigating the perils of investing in such a high-risk sector, and the country’s new government has been urged to ensure that

Scrip

Stock Watch: Bad Deals Backfire On Bayer And CSL

 
• By Andy Smith

It fell to Bayer AG and CSL Limited to wrap up the big pharma earnings season. They faced a less desirable shared challenge – lingering impacts from past deals. Quarterly Results Opacity In report